UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
houre par raenonea	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Reporting Person *		2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]			5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
	· · · · · · · · · · · · · · · · · · ·					nsactio	n (Month	n/Day/	Year)		X_Officer (give				
O, A6 M2J	(Street)		4. If Am	endn	nent, Dat	te Origi	nal Filed	(Month/I	Day/Year)		Form filed by O	ne Reporting P	erson	plicable Line)	
	(State)	(Zip)				Table I	- Non-D	erivat	tive Securitie	s Acquire	d, Disposed o	f, or Benefi	cially Owned		
curity		2. Transaction Date (Month/Day/Year	Execut any	tion 1	Date, if	Code		(A) c	or Disposed o	f (D) Ow Tra	ned Followin insaction(s)		O F D	orm: B irect (D)	. Nature f Indirect Beneficial Ownership Instr. 4)
						Cod	e V	Amo	ount (A) or (D)	Price					
		Table II					a cur iired, Dis	rently	valid OMB of, or Benef	control i	number.	nless the f	orm displays	•	
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. Transac Code	tion	5. Num Derivat Securiti Acquire or Disp (D)	ber of ive ies ed (A) osed of	6. Date Expirati (Month	Exerci ion Da	isable and te	7. Title an of Underl Securities	ying		Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
			Code	v	(A)	(D)				Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
\$ 1.25	04/13/2022		A		600,00	00	(1)	0	04/12/2032	Commo	1600 000	\$ 0	600,000	D	
	DSE BIOSE ERS ROAD, A6 M2J Eurity Eurity 2. Conversion or Exercise Price of Derivative Security	PHILIPPE (First) DSE BIOSCIENCES INC., ERS ROAD, SUITE 1105 (Street) O, A6 M2J 4R3 (State) Equivarity 2. Conversion or Exercise Price of Derivative Security (Month/Day/Year)	HILIPPE (First) (Middle) DSE BIOSCIENCES INC., 251 ERS ROAD, SUITE 1105 (Street) D, A6 M2J 4R3 (State) (Zip) Eurity 2. Transaction Date (Month/Day/Year) Table II 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year)	Aptose (First) (Middle) 3. Date of O4/13/2 SERS ROAD, SUITE 1105 (Street) 4. If Am (O, A6 M2J 4R3 (State) (Zip) Eurity 2. Transaction Date (Month/Day/Year) Execution or Exercise Price of Derivative Security (Month/Day/Year) Aptose (Middle) 3. Date of O4/13/2 4. If Am 2. Transaction Date (Execution Date and Execution Date an	Aptose Bic (First) (Middle) 3. Date of Ea 04/13/2022 ERS ROAD, SUITE 1105 (Street) 4. If Amendr Date (Month/Day/Year) Proof of Exercise Price of Derivative Security Aptose Bic (Middle) 3. Date of Ea 04/13/2022 2. Transaction Date (Month/Day/Year) Table II - Derivative (e.g., puts, 4 Transaction any (Month/Day/Year) (Month/Day/Year) Aptose Bic (Middle) 3. Date of Ea 04/13/2022 4. If Amendr Date (Execution any (Month/Day/Year) (Month/Day/Year) Aptose Bic (Middle) 3. Date of Ea 04/13/2022 4. If Amendr Date (Execution any (Month/Day/Year) (Month/Day/Year) Aptose Bic (Middle) 3. Date of Ea 04/13/2022 Aptose Bic (Middle) 4. If Amendr Date (Middle) 4. If	Aptose Bioscienc (First) (Middle) OSE BIOSCIENCES INC., 251 ERS ROAD, SUITE 1105 (Street) O, A6 M2J 4R3 (State) 2. Transaction Date (Month/Day/Year) Poport on a separate line for each class of securities beneficially owned direction or Exercise Price of Derivative Security 2. Table II - Derivative Securities (e.g., puts, calls, wa (Month/Day/Year)) Table II - Derivative Securities (e.g., puts, calls, wa (Month/Day/Year)) 4. Transaction Date (e.g., puts, calls, wa (Month/Day/Year) Aptose Bioscienc 3. Date of Earliest Transaction Execution Date, if any (Month/Day/Year) Execution Date, if any (Month/Day/Year) Aptose Bioscienc 3. Date of Earliest Transaction Execution Date, if any (Month/Day/Year) Execution Date, if any (Month/Day/Year) Aptose Bioscienc 3. Date of Earliest Transaction Execution Date, if any (Month/Day/Year) Execution Date, if any (Month/Day/Year) Aptose Bioscienc 3. Date of Earliest Transaction Execution Date, if any (Month/Day/Year) Aptose Bioscienc 3. Date of Earliest Transaction Execution Date, if any (Month/Day/Year) Aptose Bioscienc 4. If Amendment, Date Execution Date, if any (Month/Day/Year) Aptose Bioscienc 4. If Amendment, Date Execution Date, if any (Month/Day/Year) Aptose Bioscienc 4. If Amendment, Date Execution Date, if any (Month/Day/Year) Aptose Bioscienc 4. Transaction Code Code (Instr. 8) Acquire Code (Instr. 8) Acquire Aptose Bioscience Aptose Barliest Transaction Code (Instr. 8) Acquire Code (Instr. 8) Acquire Aptose Bioscience Code (Instr. 8) Acquire Code (Instr. 8) Acquire Aptose Bioscience Code (Instr. 8) Acquire Code	Aptose Biosciences Inc. (First) (Middle) (DSE BIOSCIENCES INC., 251 ERS ROAD, SUITE 1105 (Street) 4. If Amendment, Date Original Particles (Month/Day/Year) (Street) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 4. If Amendment, Date Original Particles (Month/Day/Year) (Month/Day/Year) 5. Number of Derivative Securities (Month/Day/Year) (Month/Day/Year) 6. Number of Derivative Securities (Month/Day/Year) (Month/Day/Year) 7. Number of Derivative Securities (Month/Day/Year) (Month/Day/Year) 8. Number of Derivative Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) (Code V (A) (D)	Aptose Biosciences Inc. [APTO	Aptose Biosciences Inc. [APTO] (First) (Middle) (SE BIOSCIENCES INC., 251 ERS ROAD, SUITE 1105 (Street) D, A6 M2J 4R3 (State) 2. Transaction Date (Month/Day/Year) Date (Month/Day/Year) Aptose Biosciences Inc. [APTO] 3. Date of Earliest Transaction (Month/Day/ 04/13/2022 4. If Amendment, Date Original Filed(Month/Day/ 2A. Deemed Execution Date, if any (Month/Day/Year) Amount of the privative Securities beneficially owned directly or indirectly. Table II - Derivative Securities Acquired, Disposed (e.g., puts, calls, warrants, options, conversion of Date on Execution Date any (Month/Day/Year) Aptose Biosciences Inc. [APTO] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) Aptose Date of Earliest Transaction (Month/Day/Year) Aptose Date of Earlies (Month/Day/Year) Aptose Date of Earlies Transaction (Month/Day/Year) Aptose Date of Earlies Tra	Aptose Biosciences Inc. [APTO] SE BIOSCIENCES INC., 251 ERS ROAD, SUITE 1105 (Street) A If Amendment, Date Original Filed(Month/Day/Year) A If Amendment, Date Original Filed(Month/Day/Ye	Aptose Biosciences Inc. [APTO] SE BIOSCIENCES INC., 251 Gisteet) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Anon-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securities Acquired (Month/Day/Year) 3. Transaction Date (Instr. 8) (A) or Disposed of (D) Price of Code (Instr. 8) Persons who respond to the cin this form are not required to a currently valid OMB control of Code (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (Month/Day/Year) A GOO 0000 Security A GOO 0000 (Instr. 3, 4, and 5) Date Exercisable Date (Month/Day/Year) (Instr. 3, 4, and 5) Date Expiration Date (Instr. 3, 4, and 5) Code V (A) (D) Date Exercisable Date (Instr. 3) Date Expiration Date (Instr. 3, 4, and 5) Title Code (Instr. 3, 4, and 5) Code V (A) (D) Date Exercisable Date (Instr. 3) Commod Exercisable Date (Month/Day/Year) (Instr. 3) Code V (A) (D) Date Exercisable Date (Instr. 3) Commod Exercisable Date (Instr. 3)	Aptose Biosciences Inc. [APTO] SERS ROAD, SUITE 1105 4. If Amendment, Date Original Filed(Month/Day/Year) O, A6 M2J 4R3 4. If Amendment, Date Original Filed(Month/Day/Year) O, A6 M2J 4R3 2. Transaction Date (Month/Day/Year) Date (Month/Day/Year) (Month/Day/Year) A Date (Execution Date, if Amonth/Day/Year) A Deport on a separate line for each class of securities beneficially owned directly or indirectly. Table I - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (B) (Instr. 3 and 4) A GOO OOO A Date (Month/Day/Year) A GOO OOO A Date (B) Date (Month/Day/Year) Security Security A GOO OOO A Date (Exercisable and Expiration) Date (Instr. 3 and 4) A GOO OOO A Date (Code (Noth/Day/Year)) Date (Instr. 3 and 4) A GOO OOO A Date (Code (Noth/Day/Year)) Date (Instr. 3 and 4) A GOO OOO A Date (Code (Noth/Day/Year)) Date (Instr. 3 and 4) A GOO OOO A Date (Noth/Day/Year) Date (Instr. 3 and 4) A GOO OOO A Date (Noth/Day/Year) Date (Instr. 3 and 4) Code (Noth/Day/Year) Date (Instr. 3 and 4) A GOO OOO A Date (Noth/Day/Year) Date (Instr. 3 and 4) Code (Noth/Day/Year) Date (Instr. 3 and 4)	Aptose Biosciences Inc. [APTO]	Aptose Biosciences Inc. [APTO]	Aptose Biosciences Inc. [APTO] Director Check all applicable Che

			Relationships	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
LEDRU PHILIPPE C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3			Chief Commercial Officer	

Signatures

/s/ Janet Clennett as attorney-in-fact for Philippe Ledru	04/14/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Fifty percent (50%) of the shares vest on 4/13/2023; the remaining 50% vest as follows: 1/3 on 4/13/2024; 1/3 on 4/13/2025; and 1/3 on 4/13/2026.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.